Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Belrestotug - iTeos Therapeutics

Drug Profile

Belrestotug - iTeos Therapeutics

Alternative Names: EOS 884448; EOS-448; GSK-4428859; GSK-4428859A; TIGIT antagonist monoclonal antibody - iTeos Therapeutics

Latest Information Update: 19 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator iTeos Therapeutics
  • Developer GSK; iTeos Therapeutics
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Squamous cell cancer
  • Phase I/II Haematological malignancies; Multiple myeloma; Solid tumours

Most Recent Events

  • 19 Jun 2024 Phase-III clinical trials in Non-small cell lung cancer (First-line therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable, Combination therapy) in Asia, Europe, South America, North America (IV)
  • 10 May 2024 Interim efficacy and adverse events data from a phase II trial in Non small cell lung cancer released by iTeos Therapeutics
  • 10 May 2024 iTeos Therapeutics completes enrolment in its phase I/II trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in US, Belgium, France, Italy, Spain and United Kingdom (IV) (NCT05060432)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top